December 15, 2014 | The Israeli biomedical company BioLight Lifesciences reportedly plans to launch its cancer diagnosis products in India within the next couple of months. “We will be happier to shift our focus from the US, to sell our products to India designated in particular to cervical cancer as we see a huge potential in the Indian market. This is mainly because of the increase in the number of deaths of many women in India due to cervical cancer than in the US,” says Suzana Nahum Zilberberg, CEO of BioLight. India has seen a spike in recent years in cervical cancer among women, becoming the largest cancer killer among women. BioLight is a public company traded on the Tel Aviv Stock Exchange.